Grants and Contracts Details
| Status | Finished |
|---|---|
| Effective start/end date | 9/25/18 → 9/21/23 |
Funding
- Juno Therapeutics Incorporated: $279,211.00
18-NHL-22-JT (17006) A Phase 2 study of JCAR017 as Second-Line Therapy in Adult Patients with Aggressive B-cell NHL
- Iragavarapu, Chaitanya (PI)
- Hildebrandt, Gerhard (Former PI)